Should we apply sorafenib in hepatocellular carcinoma patients with microvascular invasion after curative hepatectomy?
Open Access
- 1 January 2019
- journal article
- research article
- Published by Taylor & Francis Ltd in OncoTargets and Therapy
- Vol. ume 12, 541-548
- https://doi.org/10.2147/ott.s187357
Abstract
Objective: Microvascular invasion (MVI) has been proved to be an independent risk factor for the recurrence of HCC. If promptly treated, the recurrence rate can be reduced and the total survival time can be prolonged. The aim of this study is to analyze the effect of sorafenib on the clinical outcomes in HCC patients with MVI after curative hepatectomy. Methods: HCC patients who underwent hepatectomy and were pathologically diagnosed with MVI were retrospectively analyzed. Patients were divided into sorafenib group and control group. Sorafenib 400 mg, twice daily, was administered orally after surgery in the sorafenib group. The recurrence-free survival (RFS) and overall survival (OS) were observed during follow-up, and associated factors were analyzed using univariate and multivariate COX regression. Results: There was no significant difference in demographics, clinical staging, and tumor index between sorafenib group (16 patients) and control group (33 matched patients). The RFS and OS were both longer in the sorafenib group, and the 3-years RFS rates of the sorafenib group and control group were 56.3% (9 of 16) and 24.2% (8 of 33), respectively (P=0.027). The 3-year OS rate of the sorafenib group was 81.3% (13 of 16), which was significantly higher than that of the control group (39.4%, P=0.006). The results of multivariate COX regression indicated that treatment with sorafenib was an independent associated factor for RFS and OS. Conclusion: We believe that using sorafenib therapy after curative hepatectomy in HCC patients with MVI is effective and beneficial as it can reduce recurrence and prolong the survival time.Keywords
This publication has 39 references indexed in Scilit:
- A Systematic Review of Microvascular Invasion in Hepatocellular Carcinoma: Diagnostic and Prognostic VariabilityAnnals of Surgical Oncology, 2012
- Adjuvant therapy options following curative treatment of hepatocellular carcinoma: A systematic review of randomized trialsEuropean Journal of Surgical Oncology, 2012
- Prognostic factors after early recurrence in patients who underwent curative resection for hepatocellular carcinomaJournal of Surgical Oncology, 2010
- Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse modelJournal of Hepatology, 2010
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Perioperative Factors Affecting Long-Term Outcomes of 473 Consecutive Patients Undergoing Hepatectomy for Hepatocellular CarcinomaAnnals of Surgical Oncology, 2009
- Indicators of prognosis after liver transplantation in Chinese hepatocellular carcinoma patientsWorld Journal of Gastroenterology, 2009
- Risk factors for early death after liver resection in patients with solitary hepatocellular carcinomaJournal of Hepato-Biliary-Pancreatic Surgery, 2005
- Resection and Liver Transplantation for Hepatocellular CarcinomaSeminars in Liver Disease, 2005
- Hepatocellular carcinoma in Central Europe: prognostic features and survivalGut, 2001